Sentiment-Signal
23,9
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Unternehmen & Branche
| Name | AN2 Therapeutics, Inc. |
|---|---|
| Ticker | ANTX |
| CIK | 0001880438 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 128,7 Mio. USD |
| Beta | -1,32 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -35,174,000 | -1.16 | 61,950,000 | 53,060,000 | |
| 2025-09-30 | 10-Q | -9,353,000 | -0.31 | 67,235,000 | 60,377,000 | |
| 2025-06-30 | 10-Q | -6,462,000 | -0.21 | 75,825,000 | 68,842,000 | |
| 2025-03-31 | 10-Q | -10,649,000 | -0.35 | 81,343,000 | 73,329,000 | |
| 2024-12-31 | 10-K | -51,321,000 | -1.72 | 92,087,000 | 81,849,000 | |
| 2024-09-30 | 10-Q | -12,747,000 | -0.43 | 97,689,000 | 87,672,000 | |
| 2024-06-30 | 10-Q | -14,435,000 | -0.48 | 108,481,000 | 98,354,000 | |
| 2024-03-31 | 10-Q | -16,617,000 | -0.56 | 121,260,000 | 110,597,000 | |
| 2023-12-31 | 10-K | -64,732,000 | -2.74 | 138,744,000 | 124,701,000 | |
| 2023-09-30 | 10-Q | -16,707,000 | -0.65 | 153,808,000 | 138,969,000 | |
| 2023-06-30 | 10-Q | -15,804,000 | -0.81 | 98,926,000 | 87,764,000 | |
| 2023-03-31 | 10-Q | -15,323,000 | -0.79 | 91,084,000 | 82,517,000 | |
| 2022-12-31 | 10-K | -40,956,000 | -2.79 | 102,560,000 | 95,372,000 | |
| 2022-09-30 | 10-Q | -11,339,000 | -0.59 | 110,008,000 | 105,573,000 | |
| 2022-06-30 | 10-Q | -10,120,000 | -0.53 | 120,016,000 | 115,863,000 | |
| 2022-03-31 | 10-Q | -7,655,000 | -2.98 | 120,503,000 | 115,410,000 | |
| 2021-12-31 | 10-K | -21,543,000 | -10.64 | 65,316,000 | -47,411,000 | |
| 2021-09-30 | 10-Q | -6,943,000 | -3.35 | -38,349,000 | ||
| 2021-06-30 | 10-Q | -5,007,000 | -2.62 | -29,842,000 | ||
| 2021-03-31 | 10-Q | -2,048,000 | -23,114,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-06 | Day Lucy | Officer, Chief Financial Officer | Open Market Sale | -5,512 | 1.01 | -5,578.14 | -74,7% | |
| 2026-01-06 | Eizen Joshua M | Officer, See Remarks | Open Market Sale | -6,931 | 1.01 | -7,014.17 | -94,0% | |
| 2026-01-06 | Chanda Sanjay | Officer, Chief Development Officer | Open Market Sale | -5,956 | 1.01 | -6,027.47 | -80,7% | |
| 2026-01-05 | Eizen Joshua M | Officer, See Remarks | Open Market Sale | -17,923 | 1.00 | -17,948.09 | -240,4% | |
| 2026-01-05 | Day Lucy | Officer, Chief Financial Officer | Open Market Sale | -3,295 | 1.00 | -3,304.89 | -44,3% | |
| 2026-01-05 | Chanda Sanjay | Officer, Chief Development Officer | Open Market Sale | -3,295 | 1.00 | -3,304.89 | -44,3% | |
| 2025-11-04 | Eizen Joshua M | Officer, See Remarks | Open Market Sale | -2,819 | 1.14 | -3,213.66 | -43,0% | |
| 2025-06-02 | Easom Eric | Director, Officer, Chief Executive Officer | Open Market Purchase | 10,000 | 1.07 | 10,665.00 | +142,9% | |
| 2025-05-28 | FitzPatrick Margaret M | Director | Open Market Purchase | 8,610 | 1.18 | 10,133.11 | +135,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.